SKYE has been in the news 409% more than usual
Dec 01, 2025, 3:32 PM
-44.09%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
SKYE has been in the news recently: Several law firms, including Schall Law Firm, DJS Law Group, and Gross Law Firm, are reminding investors of a class action lawsuit against Skye Bioscience, Inc. for allegedly making misleading claims between November 4, 2024, and October 3, 2025. Shareholders are encouraged to register for the class action in response to these misleading statements.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.